Journal Edition sofw journal 06-2021


This application study examined in vivo the effect of a microbiotic care product (SYMBIO® DERMAL) on dry skin prone to atopic dermatitis. The microbiotic care contained a complex of lysed, non-pathogenic Escherichia coli and Enterococcus faecalis bacteria additionally to nourishing substances. It thus follows the “emollients plus”-principle as described in the current European guidelines for treatment of atopic dermatitis [5]. Before and after applying the microbiotic care for four weeks, the following tests were carried out on defined skin testing areas: (i) determination of the transepidermal water loss (TEWL); (ii) determination of hydration, (iii) evaluation of dryness / flaking by in vivo touching evaluation, (iv) clinical-dermatological assessment with final questionnaire and (v) patch safety test. As shown after four weeks of application, the microbiotic care reduced transepidermal water loss by an average of around 22%, increased skin moisture by an average of almost 50% and reduced dryness / flaking by an average of almost 50%. Consequently, the microbiotic care supported the barrier function of dry skin. Previously performed in vitro studies also proved immunomodulatory properties of the bacterial lysate complex. According to clinical-dermatological test criteria, the microbiotic care was very well tolerated. It received the 5-star-rating (“clinically tested” & “very good”) from Dermatest.

Back to top

We use cookies on our website. Some of them are essential for the operation of the site, while others help us to improve this site and the user experience (tracking cookies). You can decide for yourself whether you want to allow cookies or not. Please note that if you reject them, you may not be able to use all the functionalities of the site.